Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma - Final Appraisal Determination

In DRAFT guidance NICE recommend autologous anti-CD19-transduced CD3+ cells for use in the Cancer Drugs Fund for relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

National Institute for Health and Care Excellence